AtaiBeckley Inc. Common Stock

AtaiBeckley shares surged 33.40% after pharmaceutical giant Eli Lilly agreed to acquire the mental health-focused biotechnology company for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The total deal valuation could reach approximately $3.8 billion if all conditions are met. The acquisition is expected to close in Q3...

AtaiBeckley completed enrollment in its Phase 2b Elumina trial for VLS-01, a DMT-based oral film treatment for treatment-resistant depression, with 156 patients randomized. The company plans to advance VLS-01 into Phase 3 development for major depressive disorder and generalized anxiety disorder, pending positive Phase 2 results expected in Q4 20...

AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biotechnology company developing mental health treatments, announced participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, HCW Neuro Perspectives Conference, and UBS Virtual CNS Day. The compa...

AtaiBeckley reported expanded Phase 2a trial results for EMP-01 (oral R-MDMA) in social anxiety disorder, demonstrating 49% responder rates and clinically meaningful improvements across multiple symptom measures (LSAS, SPIN, SAFE) with a favorable safety profile and no serious adverse events. The treatment showed a 38% reduction in patient-report...

AtaiBeckley Inc. announced that Co-Founder and CEO Dr. Srinivas Rao will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13-16) and the Needham Virtual Psychedelics Forum (April 27). The company's lead candidate BPL-003 (mebufotenin benzoate nasal spray) has received FDA Breakthrough Therapy Designation and is on track...